Europe Clinical Biomarkers Market - Analysis and Forecast, 2023-2033
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 1-5 working days.
Introduction to Europe Clinical Biomarkers Market
The Europe clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033. Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.
Market Introduction
The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services. Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe's regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess. This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.
Market Segmentation
Segmentation 1: by Country
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are
This report will be delivered in 1-5 working days.
Introduction to Europe Clinical Biomarkers Market
The Europe clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033. Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.
Market Introduction
The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services. Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe's regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess. This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.
Market Segmentation
Segmentation 1: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are
- ALCEN
- bioMйrieux S.A.
- CENTOGENE N.V.
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- QIAGEN N.V.
Executive Summary
1 MARKET
1.1 Product Definition
1.2 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.1.2.1 Open Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
4.4 COVID-19 Impact on Clinical Biomarkers Market
4.4.1 COVID-19 Impact on Market Size
4.5 Market Trends
4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
4.5.2 Increasing Biomarkers Usage in Precision Medicine
4.5.3 Technologies Being Used in Clinical Biomarker Testing
4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible
5 REGION
5.1 Overview
5.2 Europe
5.2.1 Germany
5.2.2 France
5.2.3 U.K.
5.2.4 Italy
5.2.5 Spain
5.2.6 Rest-of-Europe
6 MARKET - COMPANY PROFILES
6.1 Overview
6.2 ALCEN
6.2.1 Company Overview
6.2.2 Role of ALCEN in the Clinical Biomarkers Market
6.2.3 Analyst’s Perspective
6.3 bioMйrieux S.A.
6.3.1 Company Overview
6.3.2 Role of bioMйrieux S.A. in the Clinical Biomarkers Market
6.3.3 Corporate Strategies
6.3.3.1 Funding and Expansion
6.3.3.2 Product Launches
6.3.4 Financials
6.3.5 Analyst’s Perspective
6.4 CENTOGENE N.V.
6.4.1 Company Overview
6.4.2 Role of CENTOGENE N.V. in the Clinical Biomarkers Market
6.4.3 Business Strategies
6.4.3.1 Funding
6.4.4 Corporate Strategies
6.4.4.1 Synergistic Activities
6.4.5 Financials
6.4.6 Analyst’s Perspective
6.5 Eurofins Scientific
6.5.1 Company Overview
6.5.2 Role of Eurofins Scientific in the Clinical Biomarkers Market
6.5.1 Corporate Strategies
6.5.1.1 Product Launches
6.5.2 Financials
6.5.3 Analyst’s Perspective
6.6 F. Hoffmann-La Roche Ltd
6.6.1 Company Overview
6.6.2 Role of F. Hoffmann-La Roche Ltd in the Clinical Biomarkers Market
6.6.3 Business Strategies
6.6.3.1 Product Launches
6.6.4 Corporate Strategies
6.6.4.1 Synergistic Activities
6.6.5 Financials
6.6.6 Analyst’s Perspective
6.7 QIAGEN N.V.
6.7.1 Company Overview
6.7.2 Role of QIAGEN N.V. in the Clinical Biomarkers Market
6.7.3 Corporate Strategies
6.7.3.1 Product Launches
6.7.4 Business Strategies
6.7.4.1 Synergistic Activities
6.7.5 Financials
6.7.6 Analyst’s Perspective
1 MARKET
1.1 Product Definition
1.2 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.1.2.1 Open Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
4.4 COVID-19 Impact on Clinical Biomarkers Market
4.4.1 COVID-19 Impact on Market Size
4.5 Market Trends
4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
4.5.2 Increasing Biomarkers Usage in Precision Medicine
4.5.3 Technologies Being Used in Clinical Biomarker Testing
4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible
5 REGION
5.1 Overview
5.2 Europe
5.2.1 Germany
5.2.2 France
5.2.3 U.K.
5.2.4 Italy
5.2.5 Spain
5.2.6 Rest-of-Europe
6 MARKET - COMPANY PROFILES
6.1 Overview
6.2 ALCEN
6.2.1 Company Overview
6.2.2 Role of ALCEN in the Clinical Biomarkers Market
6.2.3 Analyst’s Perspective
6.3 bioMйrieux S.A.
6.3.1 Company Overview
6.3.2 Role of bioMйrieux S.A. in the Clinical Biomarkers Market
6.3.3 Corporate Strategies
6.3.3.1 Funding and Expansion
6.3.3.2 Product Launches
6.3.4 Financials
6.3.5 Analyst’s Perspective
6.4 CENTOGENE N.V.
6.4.1 Company Overview
6.4.2 Role of CENTOGENE N.V. in the Clinical Biomarkers Market
6.4.3 Business Strategies
6.4.3.1 Funding
6.4.4 Corporate Strategies
6.4.4.1 Synergistic Activities
6.4.5 Financials
6.4.6 Analyst’s Perspective
6.5 Eurofins Scientific
6.5.1 Company Overview
6.5.2 Role of Eurofins Scientific in the Clinical Biomarkers Market
6.5.1 Corporate Strategies
6.5.1.1 Product Launches
6.5.2 Financials
6.5.3 Analyst’s Perspective
6.6 F. Hoffmann-La Roche Ltd
6.6.1 Company Overview
6.6.2 Role of F. Hoffmann-La Roche Ltd in the Clinical Biomarkers Market
6.6.3 Business Strategies
6.6.3.1 Product Launches
6.6.4 Corporate Strategies
6.6.4.1 Synergistic Activities
6.6.5 Financials
6.6.6 Analyst’s Perspective
6.7 QIAGEN N.V.
6.7.1 Company Overview
6.7.2 Role of QIAGEN N.V. in the Clinical Biomarkers Market
6.7.3 Corporate Strategies
6.7.3.1 Product Launches
6.7.4 Business Strategies
6.7.4.1 Synergistic Activities
6.7.5 Financials
6.7.6 Analyst’s Perspective
LIST OF FIGURES
Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 2: Europe Clinical Biomarkers Market Research Methodology
Figure 3: Primary Research Methodology
Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
Figure 5: Top-Down Approach (Segment-Wise Analysis)
Figure 6: Biomarkers Used in Various Clinical Areas
Figure 7: Europe Clinical Biomarkers Market, $Billion, 2022-2033
Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
Figure 10: Use of Clinical Biomarkers in Personalized Medicine
Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 15: Europe Clinical Biomarkers Market, $Billion, 2022-2033
Figure 16: Europe: Market Dynamics
Figure 17: Europe Clinical Biomarkers Market (by Country), $Billion, 2022-2033
Figure 18: Germany Clinical Biomarkers Market, $Billion, 2022-2033
Figure 19: Share of Cancer Cases in Germany, 2020
Figure 20: France Clinical Biomarkers Market, $Billion, 2022-2033
Figure 21: U.K. Clinical Biomarkers Market, $Billion, 2022-2033
Figure 22: Italy Clinical Biomarkers Market, $Billion, 2022-2033
Figure 23: Spain Clinical Biomarkers Market, $Billion, 2022-2033
Figure 24: Rest-of-Europe Clinical Biomarkers Market, $Billion, 2022-2033
Figure 25: Total Number of Companies Profiled
Figure 26: ALCEN: Service Portfolio
Figure 27: bioMйrieux S.A.: Product Portfolio
Figure 28: bioMйrieux S.A.: Overall Financials, $Million, 2020-2022
Figure 29: bioMйrieux S.A.: Revenue (by Segment), $Million, 2020-2022
Figure 30: CENTOGENE N.V.: Service Portfolio
Figure 31: CENTOGENE N.V.: Overall Financials, $Million, 2020-2022
Figure 32: Eurofins Scientific: Service Portfolio
Figure 33: Eurofins Scientific: Overall Financials, $Million, 2020-2022
Figure 34: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 35: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
Figure 36: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
Figure 37: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
Figure 38: QIAGEN N.V.: Product Portfolio
Figure 39: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 40: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 41: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 42: QIAGEN N.V.: R&D Expenditure, $Million, 20202022
Figure 1: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 2: Europe Clinical Biomarkers Market Research Methodology
Figure 3: Primary Research Methodology
Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
Figure 5: Top-Down Approach (Segment-Wise Analysis)
Figure 6: Biomarkers Used in Various Clinical Areas
Figure 7: Europe Clinical Biomarkers Market, $Billion, 2022-2033
Figure 8: Impact of COVID-19 on Clinical Biomarkers Market
Figure 9: Usage of Artificial Intelligence (AI) in Biomarker Discovery
Figure 10: Use of Clinical Biomarkers in Personalized Medicine
Figure 11: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, % Share, 2010-2019
Figure 12: Clinical Biomarkers Market Snapshot (by Region), $Billion, 2022-2033
Figure 13: Clinical Biomarkers Market (by Region), $Billion, 2022-2033
Figure 14: Clinical Biomarkers Market (by Region), $Billion, 2022 and 2033
Figure 15: Europe Clinical Biomarkers Market, $Billion, 2022-2033
Figure 16: Europe: Market Dynamics
Figure 17: Europe Clinical Biomarkers Market (by Country), $Billion, 2022-2033
Figure 18: Germany Clinical Biomarkers Market, $Billion, 2022-2033
Figure 19: Share of Cancer Cases in Germany, 2020
Figure 20: France Clinical Biomarkers Market, $Billion, 2022-2033
Figure 21: U.K. Clinical Biomarkers Market, $Billion, 2022-2033
Figure 22: Italy Clinical Biomarkers Market, $Billion, 2022-2033
Figure 23: Spain Clinical Biomarkers Market, $Billion, 2022-2033
Figure 24: Rest-of-Europe Clinical Biomarkers Market, $Billion, 2022-2033
Figure 25: Total Number of Companies Profiled
Figure 26: ALCEN: Service Portfolio
Figure 27: bioMйrieux S.A.: Product Portfolio
Figure 28: bioMйrieux S.A.: Overall Financials, $Million, 2020-2022
Figure 29: bioMйrieux S.A.: Revenue (by Segment), $Million, 2020-2022
Figure 30: CENTOGENE N.V.: Service Portfolio
Figure 31: CENTOGENE N.V.: Overall Financials, $Million, 2020-2022
Figure 32: Eurofins Scientific: Service Portfolio
Figure 33: Eurofins Scientific: Overall Financials, $Million, 2020-2022
Figure 34: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 35: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
Figure 36: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
Figure 37: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
Figure 38: QIAGEN N.V.: Product Portfolio
Figure 39: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 40: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 41: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 42: QIAGEN N.V.: R&D Expenditure, $Million, 20202022
LIST OF TABLES
Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
Table 2: 12. List of Product/Service Offered and its Technology
Table 1: COVID-19 Impact on Clinical Biomarkers Market, 2020-2033
Table 2: 12. List of Product/Service Offered and its Technology
